55 results
Page 2 of 3
8-K
nlvifnhrf smk2c
28 Jul 21
Precipio Announces Preliminary Unaudited Q2-2021 Revenues of $2.3M
4:41pm
8-K
2pdia3aney33gfbg m93
17 May 21
Precipio Announces Q1-2021 and year-end Shareholder Update Call
11:22am
8-K
EX-1.01
z89qrakl4je0n8k1
2 Apr 21
Entry into a Material Definitive Agreement
3:00pm
8-K
x0c1z dfvj0
18 Mar 21
Precipio Announces Q4-2020 and year-end Shareholder Update Call
5:30pm
8-K
4zyha7yr 05
12 Nov 20
Precipio Announces Q3-2020 Shareholder Update Call
6:12am
8-K
hfpljh1
4 Sep 20
Precipio Announces a Shareholder Call to Discuss its COVID-19 Progress and Future Plans
4:00pm
8-K
e0o enkx1k
7 Aug 20
Precipio Announces Q2-2020 Corporate Update Call For Shareholders
4:01pm
8-K
ssemkoilyo7qly2n2rs4
22 Jul 20
Precipio Announces Q2-2020 Unaudited Pathology Services Revenue Increased Approximately 50% over Q1’20
4:00pm
8-K
iem43xnn
13 May 20
Precipio Announces Q1-2020 Corporate Update Call For Shareholders
12:00am
8-K
EX-10.1
4dhk2jc
27 Mar 20
Entry into a Material Definitive Agreement
4:19pm
8-K
xlbv y85q2
16 Mar 20
Precipio Completes the Transaction with Poplar Healthcare’s Oncometrix Hematopathology Division
4:17pm
8-K
2keobs
18 Feb 20
Precipio in advanced discussions with Poplar Healthcare towards a multi-faceted strategic partnership
4:00pm
8-K
3kaeu lkd6x
14 Jan 20
Precipio announces shareholder update call to kick off 2020
2:24pm
8-K
rk0w4mn
5 Nov 19
Precipio Announces Q3-2019 Corporate Update Call for Shareholders
4:00pm
8-K
okwqqre47qnxk 67u19p
3 Oct 19
Precipio announces shareholder update call on commercial progress
12:00am
8-K
23wg9kp7lgbto6
26 Sep 19
Clinical Validations for IV-Cell™ and HemeScreen™ Completed
4:43pm
8-K
3gpjvkyn
20 Jun 19
Precipio CEO Provides Update Letter To Shareholders
5:03pm
8-K
hzebpojrzcj7 y3
26 Apr 19
Amendments to Articles of Incorporation or Bylaws
11:01am